### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	s)																
Name and Address of Reporting Person *     Ahn Chang Ho				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 04/10/2017							_^_		title below)			ow)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
LLE, MD 2	20850										F	orm filed by N	More than One R	eporting Person	n		
r)	(State)	(Zip)				Table I -	Non-D	erivativ	e Securi	ties Acq	uired,	Disposed	of, or Bene	ficially Own	ned		
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year)			any		-,	Code (Instr. 8)	or D		Disposed of (D) str. 3, 4 and 5)		Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	V	Amou		Price	:				(Instr. 4)		
Stock		04/10/2017			M		250,00	00 A	\$ 0.31	6,2	260,000			D			
Stock		04/10/2017				S <sup>(1)</sup>		250,00	00 D	\$ 0.7015 (2)	5 6,0	010,000			D		
Stock											500,000			I	By spouse (3)		
Report on a s	eparate line for eac						Person con form	sons w tained n displa	in this f ays a cu	orm are	not i valid	required t OMB cor	o respond	l unless th		1474 (9-02)	
			(e.g., put			arrants, o	ptions	s, conve	rtible sec	urities)			ı				
Derivative Conversion Date		) any	f Transaction De Code (Instr. 8) Ac or of (In		Deri Secu Acqu or D of (I (Inst	vative urities uired (A) isposed D) r. 3, 4,	Expiration Date		te	of Und Securit		ing		Derivative Securities Beneficiall Owned Following Reported Transaction	Owners Form of Derivati Security Direct ( or Indirect) (I)	(Ve Ownership (Instr. 4)	
			Code	V	(A)	(D)	Date Exerci			Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4	)	
\$ 0.31	04/10/2017		М		. ,	250,000	Ĺ	4) 0	3/01/20	22		250,000	\$ 0	0	D		
	g Ho  AHN PHA  45 SHADY  LLE, MD 2  Conversion or Exercise Price of Derivative Security  \$ 0.31	Stock Onversion or Exercise of Derivative Security Stock Sto	g Ho  (First) (Middle) AHN PHARMACEUTICALS, 45 SHADY GROVE ROAD, SUITE 455 (Street)  LLE, MD 20850  (State) (Zip)  ecurity 2. Transaction Date (Month/Day/Year)  Stock 04/10/2017  Stock 04/10/2017  Stock 1. Table II -  2. Table II -  2. Table II -  2. (Month/Day/Year)  (Month/Day/Year)  \$ 0.31 04/10/2017	REXALE  (Middle)  AHN PHARMACEUTICALS,  45 SHADY GROVE ROAD, SUITE 455  (Street)  LLE, MD 20850  (State)  (Zip)  Eccurity  2. Transaction Date (Month/Day/Year) All Month/E  Stock  04/10/2017  Stock  04/10/2017  Stock  Report on a separate line for each class of securities beneficial any (Month/Day/Year)  2. Table II - Derivative (e.g., put: any (Month/Day/Year))  (Month/Day/Year)  3A. Deemed Execution Date any (Month/Day/Year)  (Regular - Derivative (e.g., put: any (Month/Day/Year))  (A. Deemed Execution Date in any (Month/Day/Year))	g Ho  (First) (Middle) AHN PHARMACEUTICALS, 45 SHADY GROVE ROAD, SUITE 455  (Street)  (Street)  (LLE, MD 20850 (State)  (Zip)  (Month/Day/Year)  (Month/Day/Year)  Stock  2A. Deemed Execution Date (Month/Day/Year)  (Month/Day/Year)  Stock  04/10/2017  Stock  7able II - Derivative Security  2. Transaction O4/10/2017  Stock  AHO PERIVATION OF SECURITIES	g Ho  (First) (Middle) AHN PHARMACEUTICALS, 45 SHADY GROVE ROAD, SUITE 455  (Street)  (Street)  (LLE, MD 20850  (State)  (Month/Day/Year)  (Month/Day/Year)  Stock  2. Transaction Date (Month/Day/Year)  Stock  04/10/2017  Stock  Report on a separate line for each class of securities beneficially owned or Exercise (Month/Day/Year)  Price of Derivative Security  (Month/Day/Year)  3. Date of Earliest 04/10/2017  4. If Amendment,  2A. Deemed Execution Date, if any (Month/Day/Year)  (e.g., puts, calls, w (e.g., puts, calls, w (month/Day/Year))  AHN PHARMACEUTICALS,  (Month/Day/Year)  3. Date of Earliest 04/10/2017  4. If Amendment,  2A. Deemed Execution Date, if any (month/Day/Year)  (e.g., puts, calls, w (month/Day/Year))  (Instr. 8)  Acq or Dof (Instr. 8)  Code V (A)  \$ 0.31 04/10/2017	REXAHN PHARMACE  (Middle) AHN PHARMACEUTICALS, (45 SHADY GROVE ROAD, SUITE 455  (Street)  (Street)  (Street)  (State)  (Zip)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Code  Stock  (A) 4/10/2017  (Code  Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, or or Exercise or Exercise or Exercise or Exercise or Exercise Price of Date (Month/Day/Year)  (Month/Day/Year)	REXAHN PHARMACEUTICALS, AHN PHARMACEUTICALS, (Street)  LLE, MD 20850  (State)  2. Transaction Date (Month/Day/Year)  Stock  O4/10/2017  AH Mendment, Date Original File Execution Date, if any (Month/Day/Year)  Stock  O4/10/2017  AH M  Stock  O4/10/2017  Stock  O4/10/2017  Table 1 - Non-Date (Instr. 8)  Code (Instr. 8)  Code V  Stock  O4/10/2017  Table 1 - Non-Date (Instr. 8)  Code V  Stock  O4/10/2017  Table II - Derivative Securities Acquired, Derivative Securities Securi	REXAHN PHARMACEUTICALS, 1 3. Date of Earliest Transaction (Month/Day/ 04/10/2017  4. If Amendment, Date Original Filed(Month/ Date (Month/Day/Year)  (State)  (State)  (Zip)  (Zip)  (Zip)  (Zip)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Code V Amount Case of Securities Deneficially owned directly or indirectly.  (E.S. puts, calls, warrants, options, converted any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (E.S. puts, calls, warrants, options, converted any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Amounth/Day/Year)  (E.S. puts, calls, warrants, options, converted any (Month/Day/Year)  (Month/Day/Year)	REXAHN PHARMACEUTICALS, INC. [R]  AHN PHARMACEUTICALS, 45 SHADY GROVE ROAD, SUITE 455  (Street)  LLE, MD 20850  (State)  (Zip)  (Zip)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  Stock  (A)  (A)  (Code V Amount (D)  (D)  (Code V Amount (D)  (Code V Amount (D)  (D)  (Code V Amount (D)  (Code V (A)  (Code	REXAHN PHARMACEUTICALS, INC. [RNN]  AHN PHARMACEUTICALS,  (Street)  LLE, MD 20850  (Street)  LLE, MD 20850  (Street)  LLE, MD 20850  (Street)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  And (Instr. 8)  Code V Amount (D) Price (Instr. 3, 4 and 5)  (A) Or Or Or Or Seprense (Month/Day/Year)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired (Acg., puts, calls, warrants, options, convertible securities)  Acquired (A) Or Disposed of Disposed	REXAHN PHARMACEUTICALS, INC. [RNN]  AHN PHARMACEUTICALS, 45 SHADY GROVE ROAD, SUITE 455  LLE, MD 20850  Cecurity  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  Stock  D4/10/2017  Table I - Non-Derivative Securities Acquired, Or Disposed of (D) (Instr. 3, 4 and 5)  Stock  D4/10/2017  Stock  D4/10/2017  Table I - Non-Derivative Securities Acquired (A) 5. A correction Date, if or Exercise (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned directly or indirectly.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned in this form are not form displays a currently valid and 5).  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Derivative Securities (Instr. 8)  Stock  D4/10/2017  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Derivative Securities  Code (Instr. 8)  S. Number of G. Date Exercisable and 7, Title and 5).  Code V (A) (D)  Date Expiration Date (Instr. 3) and 5).  Code V (A) (D)  Sources (Instr. 3) and 5).  Code V (A) (D)  Date Expiration Date (Instr. 3) and 5).  Common Stock	REXAHN PHARMACEUTICALS,   No.   (RNN	REXAHN PHARMACEUTICALS, INC. [RNN]   (Check   Check   Check	REXAHN PHARMACEUTICALS, (NC. [RNN]  AFIN PHARMACEUTICALS, (Sixes)  4. SHADY GROVE ROAD, SUITE 455  4. If Amendment, Date Original Filedotomic Day/Year)  (Sixes)  4. If Amendment, Date Original Filedotomic Day/Year)  (Month/Day/Year)  (Month/Day/Y	REXAHN PHARMACEUTICALS, INC. [RNN] 3. Date of Earliest Transaction (Month/Day/Year) 04/10/2017 4. If Amendment, Date Original FiledoMonth/Day/Year) 04/10/2017  Table 1- Non-Derivative Securities Acquired, Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  Table 1- Non-Derivative Securities Acquired (A) or Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  Table 1- Non-Derivative Securities Acquired (A) or Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  Table 1- Non-Derivative Securities Acquired (A) or Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  Table 1- Non-Derivative Securities Acquired (A) or Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  Table 1- Non-Derivative Securities Acquired (A) or Disposed of, Dr. Gomer (Appendix Reported) 1. Stock 04/10/2017  M 250,000 A 5 0.31 6.260,000  D (Instr. 4)  Stock 04/10/2017  Table 1- Derivative Securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table 1- Derivative Securities Securities (Instr. 3)  Table 1- Derivative Securities Securities Securities Securities Securities (Instr. 3)  Table 1- Derivative Securities	

Donastino Ossara Nassa / Addissos	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Ahn Chang Ho							
C/O REXAHN PHARMACEUTICALS, INC.	X						
15245 SHADY GROVE ROAD, SUITE 455	Λ						
ROCKVILLE, MD 20850							

# **Signatures**

/s/ Tae Heum Jeong, as attorney-in-fact for Chang Ho Ahn	04/12/2017
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016.
- The price of \$0.7015 per share represents a weighted average. The shares were sold in multiple transactions at prices ranging from \$0.70 to \$0.709 per share, inclusive. The reporting (2) person undertakes to provide upon request of the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number

of shares sold at each separate price within the range set forth herein.

- (3) The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- (4) The options vested and became exercisable based on the following schedule: 75,000 on March 1, 2014, 75,000 on March 1, 2015 and 100,000 on March 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.